ProCE Banner Activity

Beantwortung wichtiger Fragen zur optimalen Behandlung von Patientinnen und Patienten mit rezidivierter/refraktärer chronischer lymphatischer Leukämie

Clinical Thought

Bei dieser Aktivität befassen sich Expertinnen und Experten mit Schlüsselfragen zur Behandlung von Patientinnen und Patienten mit rezidivierter/refraktärer (R/R) chronischer lymphatischer Leukämie (CLL), wie sie in einem live abgehaltenen Roundtable-Webinar diskutiert wurden. Diese Antworten liefern umsetzbare, anwendbare Informationen, die vielbeschäftigte Fachkräfte im Gesundheitswesen in der Klinik nutzen können.

Released: December 20, 2024

Expiration: December 19, 2025

Share

Faculty

Othman Al-Sawaf

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Farrukh T. Awan

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Alessandra Tedeschi

Alessandra Tedeschi, MD

Consultant in Hematology
Division of Hematology
Niguarda Hospital
Milano, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Othman Al-Sawaf, MD: consultant/advisor/speaker: AbbVie, Adaptive, AstraZeneca, BeiGene, Gilead, Janssen, Lilly, Roche; researcher: AbbVie, BeiGene, Janssen, Roche.

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh T. Awan, MD, MS, MBA: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADCT Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Dava Oncology, Genmab, Incyte, Kite, Loxo Oncology; researcher: AbbVie/Pharmacyclics.

Alessandra Tedeschi, MD

Consultant in Hematology
Division of Hematology
Niguarda Hospital
Milano, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Johnson & Johnson, Lilly.